APO Research
Talk to an analyst

APO RESEARCH · REPORT

GM1 Gangliosidosis Treatment

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global GM1 Gangliosidosis Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

19 December 2025179 pages

Choose your research edition.

Industry ResearchGM1 Gangliosidosis Treatment Industry Research Report 2026112 pages · $2,950 USDIndustry Growth & TrendsGlobal GM1 Gangliosidosis Treatment Industry Growth and Trends Forecast to 203273 pages · $3,450 USDMarket StructureGlobal GM1 Gangliosidosis Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032179 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal GM1 Gangliosidosis Treatment Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal GM1 Gangliosidosis Treatment Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global GM1 Gangliosidosis Treatment market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for GM1 Gangliosidosis Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for GM1 Gangliosidosis Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for GM1 Gangliosidosis Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for GM1 Gangliosidosis Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of GM1 Gangliosidosis Treatment include Axovant Gene Therapies Ltd and Passage Bio and Lysogene among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global GM1 Gangliosidosis Treatment market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of GM1 Gangliosidosis Treatment and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents GM1 Gangliosidosis Treatment sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the GM1 Gangliosidosis Treatment market size, projected growth trends, production technologies, key applications, and end-use industries.

GM1 Gangliosidosis Treatment Segment by Company

Axovant Gene Therapies Ltd

Passage Bio and Lysogene

GM1 Gangliosidosis Treatment Segment by Type

AXO-AAV-GM1

LYS-GM101

PBGM01

GM1 Gangliosidosis Treatment Segment by Application

Type 3 GM1 Gangliosidosis

Type 2 GM1 Gangliosidosis

Type 1 GM1 Gangliosidosis

GM1 Gangliosidosis Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GM1 Gangliosidosis Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of GM1 Gangliosidosis Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GM1 Gangliosidosis Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the GM1 Gangliosidosis Treatment market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of GM1 Gangliosidosis Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of GM1 Gangliosidosis Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of GM1 Gangliosidosis Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. GM1 Gangliosidosis Treatment Industry Trends Table 2. GM1 Gangliosidosis Treatment Industry Drivers Table 3. GM1 Gangliosidosis Treatment Industry Opportunities and Challenges Table 4. GM1 Gangliosidosis Treatment Industry Restraints Table 5. Global GM1 Gangliosidosis Treatment Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global GM1 Gangliosidosis Treatment Revenue Market Share by Manufacturers (2021-2026) Table 7. Global GM1 Gangliosidosis Treatment Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global GM1 Gangliosidosis Treatment Sales Market Share by Manufacturers Table 9. Global GM1 Gangliosidosis Treatment Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global GM1 Gangliosidosis Treatment Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global GM1 Gangliosidosis Treatment Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global GM1 Gangliosidosis Treatment Manufacturers, Product Type & Application Table 13. Global GM1 Gangliosidosis Treatment Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global GM1 Gangliosidosis Treatment by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of AXO-AAV-GM1 Table 17. Major Manufacturers of LYS-GM101 Table 18. Major Manufacturers of PBGM01 Table 19. Global GM1 Gangliosidosis Treatment Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global GM1 Gangliosidosis Treatment Sales by Type (2021-2026) & (K Units) Table 21. Global GM1 Gangliosidosis Treatment Sales by Type (2027-2032) & (K Units) Table 22. Global GM1 Gangliosidosis Treatment Sales Market Share by Type (2021-2026) Table 23. Global GM1 Gangliosidosis Treatment Sales Market Share by Type (2027-2032) Table 24. Global GM1 Gangliosidosis Treatment Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 25. Global GM1 Gangliosidosis Treatment Revenue by Type (2021-2026) & (K Units) Table 26. Global GM1 Gangliosidosis Treatment Revenue by Type (2027-2032) & (K Units) Table 27. Global GM1 Gangliosidosis Treatment Revenue Market Share by Type (2021-2026) Table 28. Global GM1 Gangliosidosis Treatment Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Type 3 GM1 Gangliosidosis Table 30. Major Manufacturers of Type 2 GM1 Gangliosidosis Table 31. Major Manufacturers of Type 1 GM1 Gangliosidosis Table 32. Global GM1 Gangliosidosis Treatment Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global GM1 Gangliosidosis Treatment Sales by Application (2021-2026) & (K Units) Table 34. Global GM1 Gangliosidosis Treatment Sales by Application (2027-2032) & (K Units) Table 35. Global GM1 Gangliosidosis Treatment Sales Market Share by Application (2021-2026) Table 36. Global GM1 Gangliosidosis Treatment Sales Market Share by Application (2027-2032) Table 37. Global GM1 Gangliosidosis Treatment Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global GM1 Gangliosidosis Treatment Revenue by Application (2021-2026) & (K Units) Table 39. Global GM1 Gangliosidosis Treatment Revenue by Application (2027-2032) & (K Units) Table 40. Global GM1 Gangliosidosis Treatment Revenue Market Share by Application (2021-2026) Table 41. Global GM1 Gangliosidosis Treatment Revenue Market Share by Application (2027-2032) Table 42. Global GM1 Gangliosidosis Treatment Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global GM1 Gangliosidosis Treatment Sales by Region (2021-2026) & (K Units) Table 44. Global GM1 Gangliosidosis Treatment Sales Market Share by Region (2021-2026) Table 45. Global GM1 Gangliosidosis Treatment Sales Forecasted by Region (2027-2032) & (K Units) Table 46. Global GM1 Gangliosidosis Treatment Sales Forecasted Market Share by Region (2027-2032) Table 47. North America GM1 Gangliosidosis Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 48. North America GM1 Gangliosidosis Treatment Sales by Country (2021-2026) & (K Units) Table 49. North America GM1 Gangliosidosis Treatment Sales by Country (2027-2032) & (K Units) Table 50. Europe GM1 Gangliosidosis Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. Europe GM1 Gangliosidosis Treatment Sales by Country (2021-2026) & (K Units) Table 52. Europe GM1 Gangliosidosis Treatment Sales by Country (2027-2032) & (K Units) Table 53. Asia Pacific GM1 Gangliosidosis Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Asia Pacific GM1 Gangliosidosis Treatment Sales by Country (2021-2026) & (K Units) Table 55. Asia Pacific GM1 Gangliosidosis Treatment Sales by Country (2027-2032) & (K Units) Table 56. South America, Middle East and Africa GM1 Gangliosidosis Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. South America, Middle East and Africa GM1 Gangliosidosis Treatment Sales by Country (2021-2026) & (K Units) Table 58. South America, Middle East and Africa GM1 Gangliosidosis Treatment Sales by Country (2027-2032) & (K Units) Table 59. Global GM1 Gangliosidosis Treatment Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global GM1 Gangliosidosis Treatment Revenue by Region (2021-2026) & (US$ Million) Table 61. Global GM1 Gangliosidosis Treatment Revenue by Region (2027-2032) & (US$ Million) Table 62. Global GM1 Gangliosidosis Treatment Revenue Market Share by Region (2021-2026) Table 63. Global GM1 Gangliosidosis Treatment Revenue Market Share by Region (2027-2032) Table 64. Axovant Gene Therapies Ltd Company Information Table 65. Axovant Gene Therapies Ltd Business Overview Table 66. Axovant Gene Therapies Ltd GM1 Gangliosidosis Treatment Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Axovant Gene Therapies Ltd GM1 Gangliosidosis Treatment Product Portfolio Table 68. Axovant Gene Therapies Ltd Recent Development Table 69. Passage Bio and Lysogene Company Information Table 70. Passage Bio and Lysogene Business Overview Table 71. Passage Bio and Lysogene GM1 Gangliosidosis Treatment Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Passage Bio and Lysogene GM1 Gangliosidosis Treatment Product Portfolio Table 73. Passage Bio and Lysogene Recent Development Table 74. Key Raw Materials Table 75. Raw Materials Key Suppliers Table 76. GM1 Gangliosidosis Treatment Distributors List Table 77. GM1 Gangliosidosis Treatment Customers List Table 78. Research Programs/Design for This Report Table 79. Authors List of This Report Table 80. Secondary Sources Table 81. Primary Sources List of Figures Figure 1. GM1 Gangliosidosis Treatment Product Image Figure 2. Global GM1 Gangliosidosis Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global GM1 Gangliosidosis Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global GM1 Gangliosidosis Treatment Sales (2021-2032) & (K Units) Figure 5. Global GM1 Gangliosidosis Treatment Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 GM1 Gangliosidosis Treatment Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. AXO-AAV-GM1 Image Figure 9. LYS-GM101 Image Figure 10. PBGM01 Image Figure 11. Global GM1 Gangliosidosis Treatment Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global GM1 Gangliosidosis Treatment Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global GM1 Gangliosidosis Treatment Sales Market Share by Type (2021-2032) Figure 14. Global GM1 Gangliosidosis Treatment Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global GM1 Gangliosidosis Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global GM1 Gangliosidosis Treatment Revenue Market Share by Type (2021-2032) Figure 17. Type 3 GM1 Gangliosidosis Image Figure 18. Type 2 GM1 Gangliosidosis Image Figure 19. Type 1 GM1 Gangliosidosis Image Figure 20. Global GM1 Gangliosidosis Treatment Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global GM1 Gangliosidosis Treatment Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global GM1 Gangliosidosis Treatment Sales Market Share by Application (2021-2032) Figure 23. Global GM1 Gangliosidosis Treatment Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global GM1 Gangliosidosis Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global GM1 Gangliosidosis Treatment Revenue Market Share by Application (2021-2032) Figure 26. North America GM1 Gangliosidosis Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 27. North America GM1 Gangliosidosis Treatment Sales Market Share by Country (2021-2032) Figure 28. U.S. GM1 Gangliosidosis Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Canada GM1 Gangliosidosis Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Mexico GM1 Gangliosidosis Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe GM1 Gangliosidosis Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe GM1 Gangliosidosis Treatment Sales Market Share by Country (2021-2032) Figure 33. Germany GM1 Gangliosidosis Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 34. France GM1 Gangliosidosis Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 35. U.K. GM1 Gangliosidosis Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Italy GM1 Gangliosidosis Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Netherlands GM1 Gangliosidosis Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific GM1 Gangliosidosis Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific GM1 Gangliosidosis Treatment Sales Market Share by Country (2021-2032) Figure 40. China GM1 Gangliosidosis Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Japan GM1 Gangliosidosis Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 42. South Korea GM1 Gangliosidosis Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Southeast Asia GM1 Gangliosidosis Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 44. India GM1 Gangliosidosis Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Australia GM1 Gangliosidosis Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa GM1 Gangliosidosis Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa GM1 Gangliosidosis Treatment Sales Market Share by Country (2021-2032) Figure 48. Brazil GM1 Gangliosidosis Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South Africa GM1 Gangliosidosis Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Saudi Arabia GM1 Gangliosidosis Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Turkey GM1 Gangliosidosis Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Argentina GM1 Gangliosidosis Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 53. UAE GM1 Gangliosidosis Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Egypt GM1 Gangliosidosis Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Chile GM1 Gangliosidosis Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Global GM1 Gangliosidosis Treatment Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global GM1 Gangliosidosis Treatment Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America GM1 Gangliosidosis Treatment Revenue (2021-2032) & (US$ Million) Figure 59. North America GM1 Gangliosidosis Treatment Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe GM1 Gangliosidosis Treatment Revenue (2021-2032) & (US$ Million) Figure 61. Europe GM1 Gangliosidosis Treatment Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific GM1 Gangliosidosis Treatment Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific GM1 Gangliosidosis Treatment Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa GM1 Gangliosidosis Treatment Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa GM1 Gangliosidosis Treatment Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. GM1 Gangliosidosis Treatment Value Chain Figure 67. Manufacturing Cost Structure Figure 68. GM1 Gangliosidosis Treatment Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • AXO-AAV-GM1
  • LYS-GM101
  • PBGM01
Applications
  • Type 3 GM1 Gangliosidosis
  • Type 2 GM1 Gangliosidosis
  • Type 1 GM1 Gangliosidosis
Companies covered
  • Axovant Gene Therapies Ltd
  • Passage Bio and Lysogene

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global GM1 Gangliosidosis Treatment Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global GM1 Gangliosidosis Treatment Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global GM1 Gangliosidosis Treatment Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global GM1 Gangliosidosis Treatment Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global GM1 Gangliosidosis Treatment Market Dynamics
  1. 2.1 GM1 Gangliosidosis Treatment Industry Trends
  2. 2.2 GM1 Gangliosidosis Treatment Industry Drivers
  3. 2.3 GM1 Gangliosidosis Treatment Industry Opportunities and Challenges
  4. 2.4 GM1 Gangliosidosis Treatment Industry Restraints
3 GM1 Gangliosidosis Treatment Market by Manufacturers
  1. 3.1 Global GM1 Gangliosidosis Treatment Revenue by Manufacturers (2021-2026)
  2. 3.2 Global GM1 Gangliosidosis Treatment Sales by Manufacturers (2021-2026)
  3. 3.3 Global GM1 Gangliosidosis Treatment Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global GM1 Gangliosidosis Treatment Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global GM1 Gangliosidosis Treatment Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global GM1 Gangliosidosis Treatment Manufacturers, Product Type & Application
  7. 3.7 Global GM1 Gangliosidosis Treatment Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global GM1 Gangliosidosis Treatment Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 GM1 Gangliosidosis Treatment Players Market Share by Revenue in 2025
  11. 3.8.3 2025 GM1 Gangliosidosis Treatment Tier 1, Tier 2, and Tier 3
4 GM1 Gangliosidosis Treatment Market by Type
  1. 4.1 GM1 Gangliosidosis Treatment Type Introduction
  2. 4.1.1 AXO-AAV-GM1
  3. 4.1.2 LYS-GM101
  4. 4.1.3 PBGM01
  5. 4.2 Global GM1 Gangliosidosis Treatment Sales by Type
  6. 4.2.1 Global GM1 Gangliosidosis Treatment Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global GM1 Gangliosidosis Treatment Sales by Type (2021-2032)
  8. 4.2.3 Global GM1 Gangliosidosis Treatment Sales Market Share by Type (2021-2032)
  9. 4.3 Global GM1 Gangliosidosis Treatment Revenue by Type
  10. 4.3.1 Global GM1 Gangliosidosis Treatment Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global GM1 Gangliosidosis Treatment Revenue by Type (2021-2032)
  12. 4.3.3 Global GM1 Gangliosidosis Treatment Revenue Market Share by Type (2021-2032)
5 GM1 Gangliosidosis Treatment Market by Application
  1. 5.1 GM1 Gangliosidosis Treatment Application Introduction
  2. 5.1.1 Type 3 GM1 Gangliosidosis
  3. 5.1.2 Type 2 GM1 Gangliosidosis
  4. 5.1.3 Type 1 GM1 Gangliosidosis
  5. 5.2 Global GM1 Gangliosidosis Treatment Sales by Application
  6. 5.2.1 Global GM1 Gangliosidosis Treatment Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global GM1 Gangliosidosis Treatment Sales by Application (2021-2032)
  8. 5.2.3 Global GM1 Gangliosidosis Treatment Sales Market Share by Application (2021-2032)
  9. 5.3 Global GM1 Gangliosidosis Treatment Revenue by Application
  10. 5.3.1 Global GM1 Gangliosidosis Treatment Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global GM1 Gangliosidosis Treatment Revenue by Application (2021-2032)
  12. 5.3.3 Global GM1 Gangliosidosis Treatment Revenue Market Share by Application (2021-2032)
6 Global GM1 Gangliosidosis Treatment Sales by Region
  1. 6.1 Global GM1 Gangliosidosis Treatment Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global GM1 Gangliosidosis Treatment Sales by Region (2021-2032)
  3. 6.2.1 Global GM1 Gangliosidosis Treatment Sales by Region (2021-2026)
  4. 6.2.2 Global GM1 Gangliosidosis Treatment Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America GM1 Gangliosidosis Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America GM1 Gangliosidosis Treatment Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe GM1 Gangliosidosis Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe GM1 Gangliosidosis Treatment Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific GM1 Gangliosidosis Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific GM1 Gangliosidosis Treatment Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa GM1 Gangliosidosis Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa GM1 Gangliosidosis Treatment Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global GM1 Gangliosidosis Treatment Revenue by Region
  1. 7.1 Global GM1 Gangliosidosis Treatment Revenue by Region
  2. 7.1.1 Global GM1 Gangliosidosis Treatment Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global GM1 Gangliosidosis Treatment Revenue by Region (2021-2026)
  4. 7.1.3 Global GM1 Gangliosidosis Treatment Revenue by Region (2027-2032)
  5. 7.1.4 Global GM1 Gangliosidosis Treatment Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America GM1 Gangliosidosis Treatment Revenue (2021-2032)
  8. 7.2.2 North America GM1 Gangliosidosis Treatment Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe GM1 Gangliosidosis Treatment Revenue (2021-2032)
  11. 7.3.2 Europe GM1 Gangliosidosis Treatment Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific GM1 Gangliosidosis Treatment Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific GM1 Gangliosidosis Treatment Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa GM1 Gangliosidosis Treatment Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa GM1 Gangliosidosis Treatment Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Axovant Gene Therapies Ltd
  2. 8.1.1 Axovant Gene Therapies Ltd Company Information
  3. 8.1.2 Axovant Gene Therapies Ltd Business Overview
  4. 8.1.3 Axovant Gene Therapies Ltd GM1 Gangliosidosis Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Axovant Gene Therapies Ltd GM1 Gangliosidosis Treatment Product Portfolio
  6. 8.1.5 Axovant Gene Therapies Ltd Recent Developments
  7. 8.2 Passage Bio and Lysogene
  8. 8.2.1 Passage Bio and Lysogene Company Information
  9. 8.2.2 Passage Bio and Lysogene Business Overview
  10. 8.2.3 Passage Bio and Lysogene GM1 Gangliosidosis Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Passage Bio and Lysogene GM1 Gangliosidosis Treatment Product Portfolio
  12. 8.2.5 Passage Bio and Lysogene Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 GM1 Gangliosidosis Treatment Value Chain Analysis
  2. 9.1.1 GM1 Gangliosidosis Treatment Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 GM1 Gangliosidosis Treatment Production Mode & Process
  6. 9.2 GM1 Gangliosidosis Treatment Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 GM1 Gangliosidosis Treatment Distributors
  9. 9.2.3 GM1 Gangliosidosis Treatment Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst